Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3N2 Challenge Agent Safety and Attack Rate Study
NCT04372719Phase 1Completed
- Sponsor
- SGS
- Start
- Nov 2016
- Primary completion
- Dec 2016
- Modality
- Biologic
01
Overview
Phase 1, open-label, single-arm trial of Influenza A H3N2 A/Belgium/4217/2015 in influenza, sponsored by SGS. Primary endpoints: Safety profile at 3 months, Efficacy: Infectivity at 3 months and 1 more. Started Nov 2016; status: completed.
02
Drugs
Influenza A H3N2 A/Belgium/4217/2015
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04372719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372719.